Old Web
English
Sign In
Acemap
>
authorDetail
>
Natasha Iartchouk
Natasha Iartchouk
Takeda Pharmaceutical Company
Biology
Pharmacology
Cancer
In vivo
Pharmacokinetics
4
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling
2019
Clinical Cancer Research
Dean Bottino
Mayankbhai Patel
Ekta Kadakia
Jilai Zhou
Chirag Patel
Rachel Neuwirth
Natasha Iartchouk
Rachael Brake
Karthik Venkatakrishnan
Arijit Chakravarty
Show All
Source
Cite
Save
Citations (9)
Abstract B154: Application of preclinical combination pharmacokinetic(PK)/efficacy(E) modeling to investigate and translate the preclinical scheduling effect for MLN1117 and Taxotere combination
2015
Molecular Cancer Therapeutics
Ekta Kadakia
Natasha Iartchouk
Karuppiah Kannan
Keli Song
Dong Mei Zhang
Christopher J. Zopf
Munjal Patel
Chirag Patel
Swapan Chowdhury
Wen Chyi Shyu
Jing Tao Wu
Arijit Chakravarty
Show All
Source
Cite
Save
Citations (0)
Abstract A169: Assessment of genotype-correlated sensitivity to the investigational PI3Kα selective inhibitor MLN1117 in preclinical models.
2013
Molecular Cancer Therapeutics
Natasha Iartchouk
Erik Koenig
Pooja Shah
Jeff Szwaya
Michael Fitzgerald
Dong Mei Zhang
Yueying Cao
Keli Song
Rachael Brake
Show All
Source
Cite
Save
Citations (1)
Abstract C176: The combination of mTORC1/2 and PI3Kα inhibition alleviates PI3K pathway reactivation and leads to significant antitumor activity in multiple preclinical xenograft models.
2013
Molecular Cancer Therapeutics
Rachael Brake
Robyn Fabrey
Jeff Szwaya
Michael Fitzgerald
Natasha Iartchouk
Xin Guo
Keisuke Kuida
F. Zohren
Mark Manfredi
Show All
Source
Cite
Save
Citations (2)
1